NCT04221412

Brief Summary

The purpose of this pre-approval access program is to provide treatment to immunocompromised participants with serious/life-threatening diseases or conditions (Respiratory Syncytial Virus \[RSV\] infection) and to collect the safety data to understand the safety profile of JNJ-53718678.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 7, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 9, 2020

Completed
Last Updated

August 29, 2022

Status Verified

August 1, 2022

First QC Date

January 7, 2020

Last Update Submit

August 24, 2022

Conditions

Respiratory Syncytial Virus

Interventions

JNJ-53718678DRUG

JNJ-53718678 will be administered as directed by treating physician.

Sponsors & Collaborators

MeSH Terms

Interventions

JNJ-53718678

Study Officials

  • Janssen Research & Development, LLC Clinical Trial

    Janssen Research & Development, LLC

    STUDY DIRECTOR

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 7, 2020

First Posted

January 9, 2020

Last Updated

August 29, 2022

Record last verified: 2022-08